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Hyperinsulinism Caused by Paternal-Specific
Inheritance of a Recessive Mutation in the
Sulfonylurea-Receptor Gene
Benjamin Glaser, Fergus Ryan, Marc Donath, Heddy Landau, Charles A. Stanley, Lester Baker,
David E. Barton, and Paul S. Thornton
Neonatal hyperinsulinism (HI) is a genetic disorder of
pancreatic b-cells characterized by failure to suppress
insulin secretion in the presence of hypoglycemia,
resulting in brain damage or death if not adequately
treated. Germline mutations in four genes have been
associated with HI. Some patients have focal regions of
b-cell proliferation (focal HI). Seventy HI probands in
whom at least one S U R - 1 mutation was identified were
studied. Clinical data from patients with two S U R - 1
mutant alleles were compared with those from patients
with single paternally inherited mutations. Thirty-
seven probands were homozygous or compound het-
erozygous for S U R - 1 mutations. In 33 probands, only a
single mutation was identified, and in 31, the parental
origin of the proband could be determined; in 29, the
mutation was on the paternal allele (P < 0.0002). For
three of these, pancreatic tissue was available and
showed focal b-cell hyperplasia. DNA extracted from the
focal lesion and adjacent normal pancreas revealed loss
of the maternal chromosome 11p15, resulting in reduc-
tion to homozygosity for the S U R - 1 mutation within
the focal lesion only. Using the Tdt-mediated dUTP nick
end labeling (TUNEL) reaction, apoptotic b-cells were
identified exclusively within the focal region. At diag-
nosis, disease severity was similar in patients with
paternally inherited mutations and those with two
mutations. For patients who did not undergo surgery,
those with only paternal mutations entered clinical
remission within 16 ± 6.2 months, compared with 48 ±
23 months for those with two S U R - 1 mutations (P =
0.001). In conclusion, we identified a novel mechanism
to explain the pathophysiology of focal HI and provide
evidence to suggest that this entity may be self-limiting,
since affected b-cells undergo apoptosis. D i a b e t e s
48:1652–1657, 1999
Neonatal hyperinsulinism (HI) is a genetic disorderof pancreatic b-cell function characterized byfailure to suppress insulin secretion in the pres-ence of hypoglycemia, resulting in brain damage
or death if inadequately treated. Germline mutations in four
genes have been associated with HI: the sulfonylurea recep-
tor (S U R - 1) (1), an inward rectifying potassium channel
(K i r 6.2) (2,3), glucokinase (G K) (4), and glutamate dehy-
drogenase (G L U D - 1) (5). Most patients have diffuse involve-
ment of all b-cells throughout the entire pancreas (diffuse HI).
A focal form of the disease has been described, however, in
which a discrete region of the pancreas contains hyperplas-
tic b-cells (focal HI), the rest of the pancreas being histolog-
ically entirely normal (6). Patients with focal HI have somatic
loss of part of the maternal chromosome 11p localized to the
hyperplastic region (7). The minimum region lost includes the
nonimprinted S U R - 1/K ir6.2 genes, the imprinted, maternally
expressed tumor suppressor genes H 1 9 and P 57K I P 2, and the
paternally expressed insulin-like growth factor 2 gene, I G F - 2.
This loss of expressed suppresser alleles may explain the
focal b-cell hyperplasia, but not the severe dysregulation of
insulin secretion seen in focal HI. We identified three cases
of focal HI with somatic loss of maternal chromosome 11p
associated with a mutation in the paternal S U R - 1 allele, con-
firming previous reports (8,9). This combination of events will
fully explain the focal HI phenotype and may be responsible
for most, if not all, cases of focal HI. Since focal HI cannot be
d e finitively diagnosed without surgical resection, the natural
history of the disease can only be studied if a cohort of focal
HI patients who did not undergo surgery can be identifie d
using noninvasive techniques. Genetic analysis can be used to
classify HI patients according to risk of having focal HI.
Homozygosity or compound heterozygosity for two S U R - 1
mutations suggests diffuse HI, whereas heterozygosity for a
paternally inherited S U R - 1 mutation in a HI patient is con-
sistent with focal HI. We evaluated the mutation status of a
cohort of 170 HI probands and identified 37and 29 patients that
fit each of these two criteria, respectively. We then compared
the clinical findings in medically treated patients in these two
subgroups. Our findings suggest that focal HI is very severe at
diagnosis, but that medically treated patients enter clinical
remission much faster than do patients with two mutant
S U R -1 alleles (P = 0.001). The apparent, self-limiting nature of
focal HI may be explained by an increased frequency of b- c e l l
apoptosis demonstrated within the focal lesions.
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Tdt-mediated dUTP nick end labeling.
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RESEARCH DESIGN AND METHODS
Patients. HI was diagnosed using established criteria based on the concomitant
finding of hypoglycemia, inappropriately elevated insulin levels, inappropriately
low ketone bodies, and abnormally high glucose requirement to prevent hypo-
glycemia (10,11).
Focal HI patients with histologic evaluation. Three patients with proven focal
HI were studied. The first, a non-Jewish Caucasian patient diagnosed with severe
hypoglycemia at 42 days of age, was previously reported (8). Due to lack of
response to medical treatment, surgery was recommended. A discrete region of
adenomatous b-cell hyperplasia was identified, and a 40% pancreatectomy was
performed. The second case was Ashkenazi Jewish, had severe hypoglycemia
immediately after birth, and was large for gestational age (5.36 kg), evidence of
intrauterine HI. Having failed to respond adequately to medical management, he
underwent surgery at the age of 15 days. Because the focal lesion could not be
i d e n t i fied during surgery, a 95% pancreatectomy was performed. The third
patient, a non-Jewish Caucasian, underwent partial pancreatectomy at age 8
weeks. In all cases histologic examination revealed a discrete region of adeno-
matous hyperplasia, the remainder of the pancreas being normal for age. In all,
surgery was curative.
HI cohort. DNA from 170 HI probands and their families was contributed by physi-
cians from North America, Europe, and Israel. Forty-five probands previously
underwent comprehensive mutation analysis of all 39 S U R - 1 exons using single-
strand conformational polymorphism (SSCP) analysis and direct sequencing.
The results of this study were published separately (12). The remaining probands
were screened for 24 previously reported S U R - 1 mutations (1,12–15) and for n o v e l
mutations in the 2nd nucleotide binding domain. Because of the difficulty in
obtaining comparable clinical data from all centers, the clinical comparisons
reported here were made on a subgroup of 22 patients treated by one of us (H.L.).
All ascertainments and treatment decisions were made before the mutation sta-
tus of any patient was known.
Laboratory methods. DNA was extracted from peripheral lymphocytes using
standard methods. Genomic DNA was screened for 24 previously published 
HI-associated S U R - 1 mutations using published materials and methods (1,12–15)
and for novel mutations in the 2nd nucleotide binding domain using SSCP as pre-
viously described (12).
DNA was isolated from fixed paraffin-embedded pancreatic tissue using standard
procedures. Mutations were detected by restriction fragment length polymorphism
(RFLP) analysis as previously described (1). To confirm loss of the entire terminal
segment of chromosome 11p, two informative polymorphic markers were genotyped
in each case. Tyrosine hydroxylase (T H), which is located at the p terminus of chro-
mosome 11, was used for all three cases. One additional informative marker located
centromeric to TH was genotyped for each of the three cases (GATA 1 7 G 0 4 ,
G ATA17G04, and GGAA17G05). Microsatellite analysis was performed using Ampli-
taq Gold (Perkin-Elmer, Norwalk, CT) for polymerase chain reaction (PCR) and ana-
lyzed on a 9% denaturing long-range gel electrophoresed in a Pharmacia ALF (Upp-
sala, Sweden) automated sequencing system.
Apoptotic b-cells were identified by the terminal deoxynucleotidyl trans-
ferase-mediated dUTP-X 39 nick end labeling (TUNEL) technique (16). Paraffin
sections were deparaffinized, rehydrated, and incubated with 20 µg/ml pro-
teinase K (Boehringer-Mannheim, Mannheim, Germany) for 15 min at 37°C.
TUNEL staining was accomplished using the In Situ Cell Death Detection k i t
( B o e h r i n g e r-Mannheim) according to the manufacturer’s directions. Sections
were then incubated for 30 min at 37°C with guinea pig anti-human insulin anti-
body diluted 1:50 (Dako, Glostrup, Denmark) followed by detection using a strep-
tavidin-biotin-peroxidase complex developed with aminoethylcarbazole (Zymed,
San Francisco, CA). Finally, sections were counterstained with hematoxylin and
embedded in Kaiser’s glycerol gelatin (Merck, Darmstadt, Germany). In an effort
to obtain an objective estimate of the number of apoptotic b-cells in the specimens,
a strict histologic definition of apoptosis was used. b-Cells were defined as apop-
totic only if anti-insulin antibody–labeled cells exhibited sharply demarcated,
condensed TUNEL-positive nuclei. Using this definition, it is unlikely that
necrotic cells were counted; however, it is possible that cells in different stages
of apoptosis were not counted since they did not fit the strict criteria. Trial counts
using less strict criteria demonstrated even larger differences between the focal
and “normal” regions of the pancreas (data not shown). To estimate the prevalence
of apoptotic b-cells, 100 b-cells were identified in each of 10 random high-pow-
ered fields of hyperplastic and normal regions of the pancreas. Only fields with
c l e a r, homogeneous staining were included, and fields at the periphery of the sec-
tion were avoided if any evidence of necrosis or tissue damage was present. The
number of definitely positive apoptotic nuclei was counted and hyperplastic and
normal regions compared by Fisher’s exact test.
Group data are given as means ± SD, and statistical comparisons were made
using Fisher’s exact test.
R E S U LT S
Focal HI cases. Focal lesions were reported in six patients
in whom at least one S U R - 1 mutation was identified. Three
of these were from the group that underwent mutation
screening of all S U R - 1 exons, and three were from the group
that was screened for both known mutations and for novel
mutations in the 2nd S U R - 1 nucleotide binding domain. In all
six, the proband inherited the S U R - 1 mutation on the pater-
nal allele of chromosome 11p. Histologic samples were avail-
able for confirmation and further study only from the latter
three cases, and the further analysis described here was per-
formed only on these three confirmed focal cases. In each, a
different mutation was identified, nt1630 gfi t, nt3992 gfi a ,
and R1494Q. The first two of these mutations have previ-
ously been reported in patients with classical autosomal
recessive HI in whom mutations where identified on both
S U R - 1 alleles (12,17). DNA extracted from the hyperplastic
region of the pancreases contained almost exclusively the
mutant allele as demonstrated both by the analysis of infor-
mative flanking polymorphic markers (Fig. 1) and by analy-
sis of the mutation itself (Fig. 2).
FIG. 1. In all three cases, genotyping was performed on informative
polymorphic markers on chromosome 11p as described in M E T H O D S. 
A and B: Representative ALF traces of T H and GATA17B04 microsatel-
lite analysis for index case 2. h, PCR products; d, internal size marker.
Genotypes are shown for DNA extracted from peripheral blood lym-
phocytes (PBL) from the father, the mother, and the proband. Similarly,
the DNA extracted from the normal and focal regions of the pancreas
was genotyped, and the results are shown. For the proband’s PBL and
tissue DNA, maternal and paternal alleles are labeled “p” and “m.” 
C: Composite results from all three cases. The relative quantity of
maternal and paternal alleles was estimated by calculating the area
under the curve for each allele. The maternal/paternal (M/P) ratio is
shown. In each case, two informative markers were used, T H, which is
near the p terminus of the chromosome, and another informative
marker centromeric to TH (see M E T H O D S). The expected ratio of 1 is
seen in DNA extracted from peripheral blood and from the “normal”
pancreas. In contrast, a low ratio indicative of a marked preponderance
of paternal allele is seen in the adenomatous (focal) region.
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The surgical specimens were evaluated for evidence of
apoptosis (Fig. 3). Seven, three, and five apoptotic cells per
1,000 b-cells were seen in 10 random high-power fie l d s
scanned from the focal lesions of the three cases (see M E T H-
O D S). In contrast, no apoptotic b-cells were identified in the
normal regions of any of the pancreases using identical scan-
ning techniques (P < 0.004). Apoptosis was not seen in nor-
mal or pathologic tissue obtained from a patient with benign
insulinoma (data not shown).
HI patients with S U R - 1 mutations. One hundred seventy
HI probands were screened for S U R - 1 mutations as described
in M E T H O D S. Thirty-seven probands were found to have two
mutant alleles (2MUT), being either homozygotes (n = 23) or
compound heterozygotes (n = 14). In 33 probands, only a sin-
gle mutation was identified. One of these had a new mutation
not found in either parent (12), and for one, DNA was not avail-
able from either parent. Therefore, parental origin of the muta-
tion could be determined in 31 probands. In 29, the mutant
allele was inherited from the father (1MUT- PAT, P = 0.0002).
To exclude abnormal chromosome segregation in these
families, the segregation pattern of the S U R - 1 alleles was
determined using haplotype analysis in siblings of heterozy-
gous probands with paternal mutations. Nineteen (48%) of the
40 unaffected siblings carried the paternal mutation, and 8 of
these (42%) also carried the same maternal allele as the
affected sibling (Table 1). Only 1 (2.5%) of 40 siblings had HI,
h o w e v e r, and this sibling was haploidentical with the proband
at the S U R - 1 locus. Thus, although both the maternal and
paternal alleles segregated normally, the clinical disease did
not (P = 0.004). A similar analysis of the families of probands
FIG. 2. PCR amplification of DNA followed by restriction-enzyme diges-
tion and ethidium bromide–stained agarose-gel electrophoresis was
performed with DNA from all three patients. A: Representative elec-
trophoretic gel demonstrating detection of R1494Q mutation in index
case 3. The first three lanes from the left show genomic DNA extracted
from peripheral blood leukocytes (PBL) from the father, mother, and
proband. The lanes labeled “Nl” and “Focal” show DNA extracted from
fixed, paraffin-embedded normal and focal-lesion pancreatic tissue.
When applied to mutant S U R - 1, the restriction endonuclease S t u 1
digests the 233-bp PCR product to 115- and 118-bp fragments. The
wild-type allele is not digested. Genomic DNA from the mother is not
digested at all, showing that no mutant allele is present. In contrast,
genomic DNA from the father and proband, as well as DNA extracted
from the normal pancreas, is partially digested, indicating heterozy-
g o s i t y. In sharp contrast, DNA extracted from the focal lesion was
almost completely digested, demonstrating that it contained almost
exclusively the mutant allele. B: Histogram showing the ratio of rela-
tive densitometric values of similar DNA analysis on all three families.
No mutant allele was identified in any of the maternal DNA samples,
whereas the ratio of mutant/wild-type allele in genomic DNA from the
fathers and the probands as well as DNA extracted from the normal pan-
creases (Nl) showed a mutant/wild-type ratio of ~1 (range 0.6–1.3). In
sharp contrast, DNA from the focal lesion showed a marked prepon-
derance of mutant DNA (ratio 7.0 ± 3.5, P = 0.002).
FIG. 3. Photomicrographs of pancreatic tissue double stained for the
TUNEL reaction (alkaline phosphatase) and insulin (peroxidase)
from all three patients. For patient 1, two examples of the focal lesion
are given (A and B) since no normal tissue was available for study. 
For patients 2 (C and D) and 3 (E and F), normal tissue (C and E) is
shown alongside the focal lesions (D and F). The arrows mark typical 
apoptotic nuclei.
E F
DC
BA
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with two mutant S U R - 1 alleles revealed that both allele seg-
regation and affection status segregated normally (Table 1).
Furthermore, heterozygous siblings in the two-mutation
group were always unaffected regardless of whether the
mutant allele was inherited from the mother or the father.
Twenty-three 2MU T and 12 1MUT- PAT patients underwent
s u r g e r y, but pathology reports are available for only 9 and 8,
r e s p e c t i v e l y. Focal lesions were identified in six of the 1MUT- PAT
patients, but in none of the 2MUT group (Table 1, P = 0.002).
The genetic and clinical data from the 1MUT- PAT and 2MUT
patients were compared. The incidence of specific mutations
could only be compared in Ashkenazi Jewish patients since
most S U R - 1 mutations are rare, usually occurring only in sin-
gle families (12). In the Ashkenazi Jewish population >85% of
the HI-associated alleles carry either the nt3992 g ® a or the
delF1388 mutations (14). One of these two mutations was
present on 98% (n = 58) of the disease-associated alleles in
2MUT Ashkenazi patients (77% nt3992 g® a; 23% delF1388) 
and on 100% (n = 17) of disease-associated chromosomes in
1 M U T- PAT patients (76% nt3992 g® a; 24% delF1388).
The clinical phenotype and natural history of the disease
were also compared. Birth weight was similar in the two
groups: 4.04 ± 0.21 and 3.81 ± 0.16 kg for the 2MU T a n d
1 M U T- PAT groups, respectively (P = 0.31). Other, more sub-
jective clinical data were also compared. However, clinical
assessment and treatment approaches differ widely among
medical centers, detailed clinical data on many patients
referred from abroad was not available, and most centers
favor early surgical intervention. Therefore, for the study of
the natural history of the disease, we only evaluated patients
treated by one of us (H.L.) who, for the last 10 years, has advo-
cated medical treatment whenever possible for all patients,
since a substantial percentage of operated patients develop
severe diabetes at puberty (18). Thirteen patients with two
mutations and nine patients with paternal mutations, none of
which underwent pancreatectomy, were evaluated. Both
groups had patients with clinically very severe disease (7 of
13 and 3 of 9, respectively, P = 0.41). Age at diagnosis was sim-
i l a r, with 11 of 13 and 6 of 9 patients in each group, respec-
t i v e l y, presenting with hypoglycemia within the first 24 h of
life (P = 0.61). Interestingly, 8 of the 9 patients with only a sin-
gle, paternal mutation entered clinical remission, and drug
therapy could be withdrawn after 16 ± 6.2 months (range
1–56). The ninth patient is still receiving octreotide treat-
ment at the age of 7 months. In contrast, in the group with two
mutations, 9 of 13 patients still required drug therapy after 48
± 23 months (range 14–88, P = 0.001). The other four became
drug independent after 15–107 months. These findings suggest
that patients with a single paternal mutation who did not
undergo surgery enter clinical remission much earlier than do
those with two mutations.
D I S C U S S I O N
In three patients with focal HI, we demonstrated that somatic
loss of maternal chromosome 11p15 in the focal lesion
results in reduction to homozygosity for an inherited S U R - 1
mutation and causes severe disease, unresponsive to dia-
zoxide treatment.
deLonlay et al. (7) documented loss of maternal ch11p in
10 patients with focal HI. However, genomic loss of the same
region of the maternal chromosome results in Beckwith-
Weideman syndrome, a syndrome associated with usually
mild, transient, diazoxide-responsive hyperinsulinemic hypo-
glycemia in only about 30% of cases (19). Since patients with
focal HI have severe HI unresponsive to diazoxide, loss of
maternal chromosome 11p alone is not sufficient to cause the
focal HI phenotype. Diazoxide binds to the sulfonylurea
receptor causing the KAT P channel to increase the mean open
time, thereby inhibiting glucose-induced depolarization. Com-
plete loss of KAT P function caused by homozygous S U R - 1
mutations results in severe HI, unresponsive to diazoxide ( 2 0 ) .
Therefore, reduction to homozygosity of a paternal S U R - 1
mutation within the focal lesion fully explains the phenotype
seen in focal HI patients. We previously reported one focal HI
patient with reduction to homozygosity of the paternal S U R -1
mutation in the focal lesion (8), and in a follow-up study of
d e L o n l a y ’s findings, Verkarre et al. (9) reported similar fin d i n g s
in four patients. It is therefore likely that the combination of
a paternally inherited S U R - 1 mutation along with somatic
loss of the maternal allele of chromosome 11p is the genetic
etiology of most, if not all, cases of focal HI.
It is not possible to study the natural history of focal HI
d i r e c t l y, since the definitive diagnosis of a focal lesion can only
be made at the time of surgical resection. Furthermore, even
in surgically treated patients, the histologic diagnosis of focal
HI is still not accepted in all centers, and therefore uncon-
firmed histologic reports of diffuse HI cannot be accepted as
d e finitive evidence. As an alternative approach, we studied 67
HI probands in whom at least one S U R - 1 mutation was iden-
t i fied. Patients who inherited mutations on both S U R - 1 a l l e-
les (2MUT) clearly have autosomal recessive disease (AR
HI). Patients who inherited only a single mutation could also
have recessive disease if the second mutation was missed by
the screening methods used. Alternatively, they could have
disease caused by only a single mutation, such as that found
in our three index cases.
We tested the hypothesis that focal HI, because of an inher-
ited paternal S U R - 1 mutation and somatic loss of chromo-
some 11p, is a common cause of HI, and that the natural his-
tory of this form of HI is different from autosomal recessive HI.
In patients with only a single known mutant allele, highly
s i g n i ficant preponderance of paternally inherited mutations
was found (P = 0.0002). The mutation analysis techniques
TABLE 1
Comparison between probands with two known S U R - 1 m u t a-
tions (2MUT) and those with a single known mutation on the
paternal allele (1MUT- PAT )
2 M U T 1 M U T- PAT P v a l u e
Number of probands 3 7 2 9
Number of siblings 9 4 4 0
H a p l o i d e n t i c a l 2 5 * 8 0 . 5 1
H I - a f f e c t e d 2 3 † 1 † 0 . 0 0 1
Surgery performed 2 3 1 2
Histology report available 9 8 0 . 1 6
Focal lesions identified 0 6 0 . 0 0 2
* Two siblings of one affected individual were found to be
homozygous for the nt3992 g® a mutation. Both were reported
to be clinically normal, but neither was examined by a pediatric
endocrinologist and neither underwent any specific testing for
hypoglycemia. †All affected siblings were haploidentical to the
proband at the S U R - 1 l o c u s .
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used are expected to miss a significant number of mutations,
since only a sub-group of patients underwent comprehensive
SSCP analysis, and even this technique may miss 10–20% of
mutations. Furthermore, the introns and the regulatory
regions of the gene were not screened in any of the patients,
and some patients in this heterogeneous cohort may have dis-
ease caused by mutations in different genes. These limitations
of methodology readily explain the large number of patients
(100) in whom no mutation was found. However, no bias was
introduced to favor identification of mutant alleles inherited
s p e c i fically on the paternal allele, as was found in our
patients. Only 3% (n = 1) of the siblings of 1MUT- PAT
p r o b a n d s were clinically affected, whereas the expected 24%
(n = 8) were haploidentical to the proband. This is not con-
sistent with the hypothesis that mutations are in fact present
on the maternal allele in all cases but were missed for tech-
nical reasons. Similarly, the alternative hypothesis that the
unexpected low incidence of disease in siblings is due to
increased mortality or decreased ascertainment efficiency is
not supported by these findings. Therefore, our finding that
the mutation was on the paternal allele in 29 of 31 probands
with a single mutation cannot be explained on the basis of any
known methodologic issue.
There is no evidence to suggest that the findings reported
here can be explained on the basis of imprinting or allele-
s p e c i fic expression of S U R - 1 itself. All siblings of 2MUT HI
probands who were heterozygous for paternally inherited
S U R - 1 mutations were clinically unaffected.
The clinical characteristics of 2MUT and 1MUT- PAT
probands were compared. Onset of disease and clinical s e v e r-
ity was similar, consistent with the findings of deLonlay et al.
and Verkarre et al. (7,9) for patients with proven focal HI.
1 M U T- PAT patients entered clinical remission significantly ear-
lier than 2MUT patients, however. We found an increased
number of apoptotic cells in the focal lesions when com-
pared with the rest of the pancreas in all our three patients,
suggesting that homozygosity for S U R - 1 mutations may be
associated with increased b-cell apoptosis. Miki et al. (21)
reported a transgenic mouse model that overexpresses a
mutant K i r 6 . 2 that disrupts KAT P channel activity in a manner
analogous to the HI-associated S U R - 1 mutations. These mice
had hyperinsulinemic hypoglycemia (analogous to human
HI) in the newborn period, followed by diabetes, associated
with b-cell loss attributed to apoptosis. The same group sub-
sequently reported a K i r 6 . 2 knockout mouse model (22).
I n t e r e s t i n g l y, K i r 6.2– / – mice lack b-cell KAT P channels and
have neonatal hypoglycemia and markedly impaired glucose-
stimulated insulin secretion, but as adults have only mild
glucose intolerance. The reason for the difference in clinical
expression of the two mouse models is unclear; however, the
later phenotype is similar to that seen in some HI patients after
partial pancreatectomy (23). In the K i r 6 .2– / – mice, the tran-
sient nature of the hypoglycemia may be due to decreased 
b-cell mass, and the minimal glucose intolerance may be due
to primary or secondary increased sensitivity to insulin, the
mechanism of which has yet to be established. Kagimoto et
al. (24) demonstrated apoptotic cell death in b-cells exposed
to glibenclamide, a drug of the sulfonylurea class that binds
to S U R - 1, closing the KAT P channel. Efanova et al. (25)
demonstrated that either hyperglycemia or tolbutamide, a
sulfonylurea, can induce apoptosis in b-cells isolated from
o b/o b mice and Wistar rats. Apoptosis could be inhibited by
either diazoxide, an antagonist of sulfonylurea effects on
S U R - 1, or D-600, a blocker of L-type calcium channels, sug-
gesting that opening of L-type calcium channels and resultant
increased intracellular calcium concentration played an
important role in regulating apoptosis. These findings appear
to conflict with those of Zhou et al. (26), who demonstrated
apoptosis secondary to depletion of intracellular calcium
stores, independent of changes in intracellular calcium con-
centrations. This apparent conflict may be due to the fact that
the later study was carried out primarily in the MIN6 cell line
and apoptotic signaling in cell lines may be different from that
of primary b-cells in culture. This is suggested by the obser-
vation that 10 times higher concentrations of thapsigargin, a
drug that depletes intracellular stores, were required in con-
firmatory experiments on primary cultures of mouse islets.
R e c e n t l y, I G F - 2 was shown to protect against apoptosis of
b-cells (27). The I G F - 2 gene is imprinted, and only the pater-
nal allele is expressed. Expression is high in the fetal and
neonatal period and decreases considerably after birth. It is
possible that the normally high prenatal I G F - 2 levels explain
the prenatal growth of the focal lesion, and the postnatal fall
of I G F - 2 explains the disappearance of the lesion during the
first several months of life. A similar increase in apoptosis may
also be present in diffuse HI and may explain the apparent
clinical improvement over time seen in these patients. Addi-
tional studies are required to confirm these hypotheses.
Our data, when taken together, provide strong evidence to
support the hypothesis that as many as 40% of HI patients may
have a single, paternally inherited S U R - 1 mutation and a sec-
ond non-Mendelian event (somatic loss of chromosome 11p)
causing expression of the recessive disease trait. This series
of events fully explains the clinical and genetic data pre-
sented here. In the affected clone, all KAT P channels are
mutated, the maternally expressed tumor suppresser genes
are lost, and the paternally expressed growth factor, I G F - 2,
is expressed. To g e t h e r, this will result in proliferation of cells
unable to turn off insulin secretion in the presence of hypo-
glycemia. The precise timing of the somatic event will deter-
mine the severity and age of onset of clinical disease and the
extent of pancreatic involvement. The latter can be limited to
a small lesion or to a major portion of the pancreas.
The role of KAT P mutations in the genetic susceptibility to
type 2 diabetes is still controversial. Several studies have
demonstrated associations between common S U R - 1 o r
K i r 6 . 2 polymorphisms and diabetes (28–31). Recently, Gok-
sel et al. (32) reported the association between an appar-
ently silent S U R - 1 mutation and hyperinsulinemia in nondi-
abetic subjects. These polymorphisms themselves do not
appear to have major effects on the functional characteristics
of the channel, and the association may be due to unidenti-
fied mutations in the regulatory regions of the genes or in
o t h e r, closely linked genes.
Our findings of the association between major defects in
KAT P channel activity and apoptosis suggest that subtle
changes in channel function may have major consequences
over the life of a patient. Although speculative at this point,
these findings may have implications for the pathogenesis and
the treatment of type 2 diabetes. Mutations that cause less dra-
matic changes in channel activity may modulate apoptosis.
Furthermore, sulfonylureas, the most common drugs used for
treating non–insulin-requiring diabetic patients, cause KAT P
channels to close in a manner analogous to that seen in HI
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patients. Our findings, supported by those of others (24,25),
raise the possibility that these drugs may be increasing apo-
ptosis of b-cells, thus hastening the deterioration of b- c e l l
function characteristic of patients with this disease. Clearly,
this requires direct study before any clinical decisions can be
made based on this speculation.
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